株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

原薬 (API) - 世界市場展望

Active Pharmaceutical Ingredients - Global Market Outlook (2017-2026)

発行 Stratistics Market Research Consulting 商品コード 521334
出版日 ページ情報 英文 151 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=107.66円で換算しております。
Back to Top
原薬 (API) - 世界市場展望 Active Pharmaceutical Ingredients - Global Market Outlook (2017-2026)
出版日: 2018年09月01日 ページ情報: 英文 151 Pages
概要

当レポートでは、原薬(API:医薬有効成分)の世界市場に注目し、取引規模の推移を薬剤タイプ、製剤設計、製造者の事業形態、製剤形式、原薬タイプ、分子サイス、用途、地域の別に分析・予測するほか、その全体動向を展望すべく、企業再編、新製品発売、事業進出などの重要展開をまとめています。

第1章 エグゼクティブサマリー

第2章 はじめに

  • 概略
  • ステークホルダー
  • 調査範囲
  • 調査方法
    • データマイニング
    • データ分析
    • データ検証
    • 調査手法
  • 調査情報源
    • 一次情報源(直接取材先)
    • 二次情報源(情報検索など)
    • 前提

第3章 市場動向分析

  • イントロダクション
  • 推進要因
  • 制約要因
  • 発展機会
  • 脅威
  • 用途分析
  • 新興市場
  • 今後に向けての市場シナリオ

第4章 Porterのファイブフォース分析

  • 売り手の交渉力
  • 買い手の交渉力
  • 代用品の脅威
  • 新規参入者の脅威
  • 競合

第5章 原薬の世界市場 - 薬剤タイプ別

  • イントロダクション
  • 一般処方薬
  • 革新的医薬品
  • 市販(OTC)薬
  • 処方薬
  • 効能
    • 効力区分:低 - 中
    • 効力区分:中 - 高

第6章 原薬の世界市場 - 製剤設計別

  • イントロダクション
  • 革新的原薬
  • 一般的原薬

第7章 原薬の世界市場 - 製造者の事業形態

  • イントロダクション
  • 契約メーカー
  • 自社製造
  • マーチャントメーカー
    • 一般マーチャントメーカー
    • 革新的マーチャントメーカー

第8章 原薬の世界市場 - 製剤形式別

  • イントロダクション
  • バイオテクノロジー原薬
    • 種別
    • 発現系統
    • 製品
  • 合成原薬
    • 一般原薬
    • 革新的原薬

第9章 原薬の世界市場 - 原薬タイプ別

  • イントロダクション
  • 生物学原薬
  • 化学原薬

第10章 原薬の世界市場 - 分子サイズ別

  • イントロダクション
  • 高分子薬
  • 低分子薬

第11章 原薬の世界市場 - 用途別

  • イントロダクション
  • 抗糖尿病薬
  • 心疾患
  • 中枢神経系・神経障害
  • 糖尿病
  • 内分泌学
  • 消化器疾患
  • 筋骨格治療薬
  • 非ステロイド抗炎症薬
  • 腫瘍学
  • 整形外科疾患
  • 呼吸器学
  • 泌尿器学
  • その他の用途

第12章 原薬の世界市場 - 地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • その他欧州
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • ニュージーランド
    • 韓国
    • その他アジア太平洋地域
  • 南米
    • アルゼンチン
    • ブラジル
    • チリ
    • その他南米
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • 南アフリカ
    • その他中東・アフリカ

第8章 重要展開

  • 協定、提携、協力、合弁事業
  • M&A(事業統合・買収)
  • 新製品発売
  • 事業進出
  • その他の重要施策

第9章 企業プロファイリング

  • Teva Active Pharmaceutical Industries Limited
  • Ranbaxy Laboratories
  • Pfizer, Inc
  • Novartis
  • Mylan N.V
  • Lupin
  • Dr. Reddy's Lab
  • Boehringer Ingelheim GmbH
  • Aurobindo pharma
  • Albemarle Corporation
  • Ceva Animal Health, Inc.
  • Virbac
  • Sun Pharmaceutical Industries Ltd.
  • Merck Animal Health(米)
  • Elanco Animal Health(米)
  • Zoetis(米)
  • Merial Inc. (Sanofi) (仏)
  • Bioniche Animal Health(カナダ)
  • Bayer Healthcare(独)
  • ELI Lilly and Company
  • Glaxosmithkline PLC
  • Abbvie Inc.
  • Sanofi
  • Bristol-Myers Squibb
図表

List of Tables

  • Table 1 Global Active Pharmaceutical Ingredients Market Outlook, By Region (2016-2026) (US $MN)
  • Table 2 Global Active Pharmaceutical Ingredients Market Outlook, By Drug Type (2016-2026) (US $MN)
  • Table 3 Global Active Pharmaceutical Ingredients Market Outlook, By Generic Prescription (2016-2026) (US $MN)
  • Table 4 Global Active Pharmaceutical Ingredients Market Outlook, By Innovative Drugs (2016-2026) (US $MN)
  • Table 5 Global Active Pharmaceutical Ingredients Market Outlook, By Over-the-counter (OTC) Drugs (2016-2026) (US $MN)
  • Table 6 Global Active Pharmaceutical Ingredients Market Outlook, By Prescription Drugs (2016-2026) (US $MN)
  • Table 7 Global Active Pharmaceutical Ingredients Market Outlook, By Potency (2016-2026) (US $MN)
  • Table 8 Global Active Pharmaceutical Ingredients Market Outlook, By Low to Moderate Potency (2016-2026) (US $MN)
  • Table 9 Global Active Pharmaceutical Ingredients Market Outlook, By Potent to Highly Potent (2016-2026) (US $MN)
  • Table 10 Global Active Pharmaceutical Ingredients Market Outlook, By API Formulation (2016-2026) (US $MN)
  • Table 11 Global Active Pharmaceutical Ingredients Market Outlook, By Innovative API (2016-2026) (US $MN)
  • Table 12 Global Active Pharmaceutical Ingredients Market Outlook, By Generic API (2016-2026) (US $MN)
  • Table 13 Global Active Pharmaceutical Ingredients Market Outlook, By Type of Manufacturer (2016-2026) (US $MN)
  • Table 14 Global Active Pharmaceutical Ingredients Market Outlook, By Contract Manufacturers (2016-2026) (US $MN)
  • Table 15 Global Active Pharmaceutical Ingredients Market Outlook, By Captive Manufacturers (2016-2026) (US $MN)
  • Table 16 Global Active Pharmaceutical Ingredients Market Outlook, By Merchant API Manufacturers (2016-2026) (US $MN)
  • Table 17 Global Active Pharmaceutical Ingredients Market Outlook, By Generic Merchant API Manufacturers (2016-2026) (US $MN)
  • Table 18 Global Active Pharmaceutical Ingredients Market Outlook, By Innovative Merchant API Manufacturers (2016-2026) (US $MN)
  • Table 19 Global Active Pharmaceutical Ingredients Market Outlook, By Type of Synthesis (2016-2026) (US $MN)
  • Table 20 Global Active Pharmaceutical Ingredients Market Outlook, By Biotech Active Pharmaceutical Ingredients (2016-2026) (US $MN)
  • Table 21 Global Active Pharmaceutical Ingredients Market Outlook, By Type (2016-2026) (US $MN)
  • Table 22 Global Active Pharmaceutical Ingredients Market Outlook, By Expression System (2016-2026) (US $MN)
  • Table 23 Global Active Pharmaceutical Ingredients Market Outlook, By Product (2016-2026) (US $MN)
  • Table 24 Global Active Pharmaceutical Ingredients Market Outlook, By Synthetic Active Pharmaceutical Ingredients (2016-2026) (US $MN)
  • Table 25 Global Active Pharmaceutical Ingredients Market Outlook, By Generic Synthetic APIs (2016-2026) (US $MN)
  • Table 26 Global Active Pharmaceutical Ingredients Market Outlook, By Innovative Synthetic APIs (2016-2026) (US $MN)
  • Table 27 Global Active Pharmaceutical Ingredients Market Outlook, By API Type (2016-2026) (US $MN)
  • Table 28 Global Active Pharmaceutical Ingredients Market Outlook, By Biological API (2016-2026) (US $MN)
  • Table 29 Global Active Pharmaceutical Ingredients Market Outlook, By Chemical API (2016-2026) (US $MN)
  • Table 30 Global Active Pharmaceutical Ingredients Market Outlook, By Molecule (2016-2026) (US $MN)
  • Table 31 Global Active Pharmaceutical Ingredients Market Outlook, By Large Molecule (2016-2026) (US $MN)
  • Table 32 Global Active Pharmaceutical Ingredients Market Outlook, By Small Molecule (2016-2026) (US $MN)
  • Table 33 Global Active Pharmaceutical Ingredients Market Outlook, By Application (2016-2026) (US $MN)
  • Table 34 Global Active Pharmaceutical Ingredients Market Outlook, By Anti-diabetic Drugs (2016-2026) (US $MN)
  • Table 35 Global Active Pharmaceutical Ingredients Market Outlook, By Cardiovascular Disease (2016-2026) (US $MN)
  • Table 36 Global Active Pharmaceutical Ingredients Market Outlook, By Central Nervous System and Neurological Disorders (2016-2026) (US $MN)
  • Table 37 Global Active Pharmaceutical Ingredients Market Outlook, By Diabetes (2016-2026) (US $MN)
  • Table 38 Global Active Pharmaceutical Ingredients Market Outlook, By Endocrinology (2016-2026) (US $MN)
  • Table 39 Global Active Pharmaceutical Ingredients Market Outlook, By Gastrointestinal Disorders (2016-2026) (US $MN)
  • Table 40 Global Active Pharmaceutical Ingredients Market Outlook, By Musculoskeletal drugs (2016-2026) (US $MN)
  • Table 41 Global Active Pharmaceutical Ingredients Market Outlook, By Non-steroidal Anti-inflammatory Drugs (2016-2026) (US $MN)
  • Table 42 Global Active Pharmaceutical Ingredients Market Outlook, By Oncology (2016-2026) (US $MN)
  • Table 43 Global Active Pharmaceutical Ingredients Market Outlook, By Orthopedic Disorders (2016-2026) (US $MN)
  • Table 44 Global Active Pharmaceutical Ingredients Market Outlook, By Respiratory (2016-2026) (US $MN)
  • Table 45 Global Active Pharmaceutical Ingredients Market Outlook, By Urology (2016-2026) (US $MN)
  • Table 46 Global Active Pharmaceutical Ingredients Market Outlook, By Other Applications (2016-2026) (US $MN)

NOTE: Tables for North America, Europe, Asia Pacific, South America and Middle East & Africa are represented in the same manner above.

目次

According to Stratistics MRC, the Global Active Pharmaceutical Ingredients Market is accounted for $151.89 billion in 2017 and is expected to reach $308.48 billion by 2026 growing at a CAGR of 8.2% from 2017 to 2026. Increase in incidence of chronic diseases, rising prevalence of cancer, technological advancements in API manufacturing, growing importance of generics, rapidly increasing geriatric population, increase in abbreviated new drug applications (ANDA) and increasing uptake of biopharmaceuticals are some factors fueling the market growth. However, factors such as stringent regulatory requirements and unfavorable drug price control policies across various countries are restricting the market growth.

Active pharmaceutical ingredients are any substance or combination of substances used in a finished pharmaceutical product with pharmacological activity. Active Pharmaceutical Ingredients are chemically and biologically active components of drugs with direct effect in cure, mitigation, treatment and prevention of diseases. An active ingredient (AI) is the ingredient in a pharmaceutical drug that is biologically active. The similar terms active pharmaceutical ingredient (API) and bulk active are also used in medicine, and the term active substance may be used for natural products. Some medication products may contain more than one active ingredient. The traditional word for the API is pharmacon or pharmakon which originally denoted a magical substance or drug.

Amongst Customer Base, Generic segment accounted for significant market share during the forecast period. Generic drugs benefit from the patent expiration of innovative drug as it makes them readily available in the market. The demand to produce quality medicines at lower and affordable costs creates a scenario, where the needs for generic drugs increase. By geography, Asia Pacific dominated the market due to the rising healthcare spending which has led to quality healthcare becoming accessible along with a higher demand for pharmaceutical products across APAC. The pharmaceuticals consumed here are mostly produced in onshore manufacturing units. Furthermore, contract manufacturing organizations are key outsourcing allies for pharmaceutical companies that supply their wares across the region.

Some of the key players in Active Pharmaceutical Ingredients market include Teva Active Pharmaceutical Industries Limited, Ranbaxy Laboratories, Pfizer, Inc, Novartis, Mylan N.V, Lupin, Dr. Reddy's Lab, Boehringer Ingelheim GmbH, Aurobindo pharma, Albemarle Corporation, Ceva Animal Health, Inc., Virbac, Sun Pharmaceutical Industries Ltd., Merck Animal Health (U.S.), Elanco Animal Health (U.S.), Zoetis (U.S.), Merial Inc. (Sanofi) (France), Bioniche Animal Health (Canada), Bayer Healthcare (Germany), ELI Lilly and Company, Glaxosmithkline PLC, Abbvie Inc., Sanofi and Bristol-Myers Squibb.

Drug Types Covered:

  • Generic Prescription
  • Innovative Drugs
  • Over-the-counter (OTC) Drugs
  • Prescription Drugs
  • Potency

API Formulations Covered:

  • Innovative API
  • Generic API

Type of Manufacturers Covered:

  • Contract Manufacturers
  • Captive Manufacturers
  • Merchant API Manufacturers

Type of Synthesises Covered:

  • Biotech Active Pharmaceutical Ingredients
  • Synthetic Active Pharmaceutical Ingredients

API Types Covered:

  • Biological API
  • Chemical API

Molecules Covered:

  • Large Molecule
  • Small Molecule

Applications Covered:

  • Anti-diabetic Drugs
  • Cardiovascular Disease
  • Central Nervous System and Neurological Disorders
  • Diabetes
  • Endocrinology
  • Gastrointestinal Disorders
  • Musculoskeletal drugs
  • Non-steroidal Anti-inflammatory Drugs
  • Oncology
  • Orthopedic Disorders
  • Respiratory
  • Urology
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country level segments
  • Market share analysis of the top industry players
  • Strategic recommendations for the new entrants
  • Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Futuristic Market Scenario

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Active Pharmaceutical Ingredients Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Generic Prescription
  • 5.3 Innovative Drugs
  • 5.4 Over-the-counter (OTC) Drugs
  • 5.5 Prescription Drugs
  • 5.6 Potency
    • 5.6.1 Low to Moderate Potency
    • 5.6.2 Potent to Highly Potent

6 Global Active Pharmaceutical Ingredients Market, By API Formulation

  • 6.1 Introduction
  • 6.2 Innovative API
  • 6.3 Generic API

7 Global Active Pharmaceutical Ingredients Market, By Type of Manufacturer

  • 7.1 Introduction
  • 7.2 Contract Manufacturers
  • 7.3 Captive Manufacturers
  • 7.4 Merchant API Manufacturers
    • 7.4.1 Generic Merchant API Manufacturers
    • 7.4.2 Innovative Merchant API Manufacturers

8 Global Active Pharmaceutical Ingredients Market, By Type of Synthesis

  • 8.1 Introduction
  • 8.2 Biotech Active Pharmaceutical Ingredients
    • 8.2.1 Type
      • 8.2.1.1 Biosimilars
      • 8.2.1.2 Innovative Biotech APIs
    • 8.2.2 Expression System
      • 8.2.2.1 Insect Expression Systems
      • 8.2.2.2 Mammalian Expression Systems
      • 8.2.2.3 Microbial Expression Systems
      • 8.2.2.4 Plant Expression Systems
      • 8.2.2.5 Yeast Expression Systems
    • 8.2.3 Product
      • 8.2.3.1 Blood Factors
      • 8.2.3.2 Cytokines
      • 8.2.3.3 Fusion Proteins
      • 8.2.3.4 Hormones and Growth Factors
      • 8.2.3.5 Monoclonal Antibodies
      • 8.2.3.6 Therapeutic Enzymes
      • 8.2.3.7 Vaccines
  • 8.3 Synthetic Active Pharmaceutical Ingredients
    • 8.3.1 Generic Synthetic APIs
    • 8.3.2 Innovative Synthetic APIs

9 Global Active Pharmaceutical Ingredients Market, By API Type

  • 9.1 Introduction
  • 9.2 Biological API
  • 9.3 Chemical API

10 Global Active Pharmaceutical Ingredients Market, By Molecule

  • 10.1 Introduction
  • 10.2 Large Molecule
  • 10.3 Small Molecule

11 Global Active Pharmaceutical Ingredients Market, By Application

  • 11.1 Introduction
  • 11.2 Anti-diabetic Drugs
  • 11.3 Cardiovascular Disease
  • 11.4 Central Nervous System and Neurological Disorders
  • 11.5 Diabetes
  • 11.6 Endocrinology
  • 11.7 Gastrointestinal Disorders
  • 11.8 Musculoskeletal drugs
  • 11.9 Non-steroidal Anti-inflammatory Drugs
  • 11.10 Oncology
  • 11.11 Orthopedic Disorders
  • 11.12 Respiratory
  • 11.13 Urology
  • 11.14 Other Applications

12 Global Active Pharmaceutical Ingredients Market, By Geography

  • 12.1 Introduction
  • 12.2 North America
    • 12.2.1 US
    • 12.2.2 Canada
    • 12.2.3 Mexico
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 UK
    • 12.3.3 Italy
    • 12.3.4 France
    • 12.3.5 Spain
    • 12.3.6 Rest of Europe
  • 12.4 Asia Pacific
    • 12.4.1 Japan
    • 12.4.2 China
    • 12.4.3 India
    • 12.4.4 Australia
    • 12.4.5 New Zealand
    • 12.4.6 South Korea
    • 12.4.7 Rest of Asia Pacific
  • 12.5 South America
    • 12.5.1 Argentina
    • 12.5.2 Brazil
    • 12.5.3 Chile
    • 12.5.4 Rest of South America
  • 12.6 Middle East & Africa
    • 12.6.1 Saudi Arabia
    • 12.6.2 UAE
    • 12.6.3 Qatar
    • 12.6.4 South Africa
    • 12.6.5 Rest of Middle East & Africa

13 Key Developments

  • 13.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 13.2 Acquisitions & Mergers
  • 13.3 New Product Launch
  • 13.4 Expansions
  • 13.5 Other Key Strategies

14 Company Profiling

  • 14.1 Teva Active Pharmaceutical Industries Limited
  • 14.2 Ranbaxy Laboratories
  • 14.3 Pfizer, Inc
  • 14.4 Novartis
  • 14.5 Mylan N.V
  • 14.6 Lupin
  • 14.7 Dr. Reddy's Lab
  • 14.8 Boehringer Ingelheim GmbH
  • 14.9 Aurobindo pharma
  • 14.10 Albemarle Corporation
  • 14.11 Ceva Animal Health, Inc.
  • 14.12 Virbac
  • 14.13 Sun Pharmaceutical Industries Ltd.
  • 14.14 Merck Animal Health (U.S.)
  • 14.15 Elanco Animal Health (U.S.)
  • 14.16 Zoetis (U.S.)
  • 14.17 Merial Inc. (Sanofi) (France)
  • 14.18 Bioniche Animal Health (Canada)
  • 14.19 Bayer Healthcare (Germany)
  • 14.20 ELI Lilly and Company
  • 14.21 Glaxosmithkline PLC
  • 14.22 Abbvie Inc.
  • 14.23 Sanofi
  • 14.24 Bristol-Myers Squibb
Back to Top